Table 2.
Microbiology of bloodstream infections by therapy group.
| Organism | Total a N = 381 |
Definitive 3GC Therapy a,b N = 65 |
Definitive Non-3GC Therapy a,b N = 316 |
|---|---|---|---|
| Enterobacter spp. | 238 (62.5) | 33 (50.7) | 205 (64.8) |
| E. cloacae | 142 (37.3) | 19 (29.2) | 123 (38.9) |
| E. aerogenes | 82 (21.5) | 14 (21.5) | 68 (21.5) |
| Other Enterobacter spp. | 14 (3.7) | 0 (0) | 14 (4.4) |
| Serratia spp. | 104 (27.3) | 21 (32.3) | 83 (26.2) |
| S. marcescens | 100 (26.2) | 19 (29.2) | 81 (25.6) |
| Other Serratia spp. | 4 (1.0) | 2 (3.1) | 2 (0.6) |
| Citrobacter spp. | 39 (10.2) | 11 (16.9) | 28 (8.8) |
| C. freundii | 21 (5.5) | 8 (12.3) | 13 (4.1) |
| Other Citrobacter spp. | 18 (4.7) | 3 (4.6) | 15 (4.7) |
a Data reported as n (%). b p < 0.05 when evaluating the distribution of Enterobacter, Serratia, and Citrobacter spp between both groups.